Glioblastoma: Therapeutic challenges, what lies ahead

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1826, Issue 2, 2012, Pages 338-349

  Lima, Flavia R S ^a   Kahn, Suzana Assad ^a   Soletti, Rossana C ^a   Biasoli, Deborah ^a   Alves, Tercia ^a   da Fonseca, Anna Carolina C ^a   Garcia, Celina ^a   Romão, Luciana ^a   Brito, José ^a   Holanda Afonso, Rosenilde ^a   Faria, Jane ^a   Borges, Helena ^a   Moura Neto, Vivaldo ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Angiogenesis; Cancer stem cell; Cancer therapy; Cytolysins; High grade glioma; Microglia

Indexed keywords

ACTINOPORIN; AFLIBERCEPT; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BRIVANIB; CARBOPLATIN; CARMUSTINE; CEDIRANIB; CINTREDEKIN BESUDOTOX; ETOPOSIDE; IRINOTECAN; ONCOLYTIC ADENOVIRUS; ONCOLYTIC VIRUS; PACLITAXEL; PAZOPANIB; PLERIXAFOR; PROTEIN TYROSINE KINASE INHIBITOR; PSEUDOMONAS EXOTOXIN TRANSFORMING GROWTH FACTOR ALPHA CONJUGATE; RAPAMYCIN; SMALL INTERFERING RNA; SONIC HEDGEHOG PROTEIN; SORAFENIB; SUNITINIB; TEMOZOLOMIDE; TEMSIROLIMUS; TP 38; TRANSMID; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANTIANGIOGENIC THERAPY; ASTROCYTOMA; BLEEDING DISORDER; BRAIN ISCHEMIA; BRAIN STEM TUMOR; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RESISTANCE; CANCER STEM CELL; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL EFFECTIVENESS; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DYSPHONIA; FATIGUE; GENE DELIVERY SYSTEM; GENE SILENCING; GERM LAYER; GLIOBLASTOMA; GLIOMA; HUMAN; HYPERTENSION; LUNG EMBOLISM; MICROGLIA; MOLECULARLY TARGETED THERAPY; MYXOMA VIRUS; NAUSEA; NONHUMAN; PRIORITY JOURNAL; RECURRENT CANCER; REVIEW; RNA INTERFERENCE; SIGNAL TRANSDUCTION; THERMODYNAMICS; TREATMENT DURATION; TREATMENT PLANNING; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION;

BRAIN NEOPLASMS; DRUG DELIVERY SYSTEMS; GLIOBLASTOMA; HEDGEHOG PROTEINS; HUMANS; MICROGLIA; NEOPLASTIC STEM CELLS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84862316690     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2012.05.004     Document Type: Review

References (137)

1. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
2. Trinchieri G. Innate inflammation and cancer: is it time for cancer prevention?. F1000 Med. Rep. 2011, 3:11.
3. Karin M., Greten F.R. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat. Rev. Immunol. 2005, 5:749-759.
4. Rothwell P.M., Fowkes F.G., Belch J.F., Ogawa H., Warlow C.P., Meade T.W. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011, 377:31-41.
5. Wu A., Wei J., Kong L.Y., Wang Y., Priebe W., Qiao W., Sawaya R., Heimberger A.B. Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro Oncol. 2010, 12:1113-1125.
6. Wu M., Pastor-Pareja J.C., Xu T. Interaction between Ras(V12) and scribbled clones induces tumour growth and invasion. Nature 2010, 463:545-548.
7. Zeppernick F., Ahmadi R., Campos B., Dictus C., Helmke B.M., Becker N., Lichter P., Unterberg A., Radlwimmer B., Herold-Mende C.C. Stem cell marker CD133 affects clinical outcome in glioma patients. Clin. Cancer Res. 2008, 14:123-129.
8. Ardebili S.Y., Zajc I., Gole B., Campos B., Herold-Mende C., Drmota S., Lah T.T. CD133/prominin1 is prognostic for GBM patient's survival, but inversely correlated with cysteine cathepsins' expression in glioblastoma derived spheroids. Radiol. Oncol. 2011, 45:102-115.
9. Yin A.H., Miraglia S., Zanjani E.D., Almeida-Porada G., Ogawa M., Leary A.G., Olweus J., Kearney J., Buck D.W. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 1997, 90:5002-5012.
10. Salven P., Mustjoki S., Alitalo R., Alitalo K., Rafii S. VEGFR-3 and CD133 identify a population of CD34+ lymphatic/vascular endothelial precursor cells. Blood 2003, 101:168-172.
11. Uchida N., Buck D.W., He D., Reitsma M.J., Masek M., Phan T.V., Tsukamoto A.S., Gage F.H., Weissman I.L. Direct isolation of human central nervous system stem cells. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:14720-14725.
12. Singh S.K., Hawkins C., Clarke I.D., Squire J.A., Bayani J., Hide T., Henkelman R.M., Cusimano M.D., Dirks P.B. Identification of human brain tumour initiating cells. Nature 2004, 432:396-401.
13. Corbeil D., Roper K., Fargeas C.A., Joester A., Huttner W.B. Prominin: a story of cholesterol, plasma membrane protrusions and human pathology. Traffic 2001, 2:82-91.
14. Wei J., Barr J., Kong L.Y., Wang Y., Wu A., Sharma A.K., Gumin J., Henry V., Colman H., Priebe W., Sawaya R., Lang F.F., Heimberger A.B. Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway. Mol. Cancer Ther. 2010, 9:67-78.
15. Louis D.N., Ohgaki H., Wiestler O.D., Cavenee W.K., Burger P.C., Jouvet A., Scheithauer B.W., Kleihues P. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007, 114:97-109.
16. Huse J.T., Phillips H.S., Brennan C.W. Molecular subclassification of diffuse gliomas: seeing order in the chaos. Glia 2011, 59:1190-1199.
17. Kleihues P., Ohgaki H. Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro Oncol. 1999, 1:44-51.
18. Jackson R.J., Fuller G.N., Abi-Said D., Lang F.F., Gokaslan Z.L., Shi W.M., Wildrick D.M., Sawaya R. Limitations of stereotactic biopsy in the initial management of gliomas. Neuro Oncol. 2001, 3:193-200.
19. Siebzehnrubl F.A., Reynolds B.A., Vescovi A., Steindler D.A., Deleyrolle L.P. The origins of glioma: E Pluribus Unum?. Glia 2011, 59:1135-1147.
20. Crawford F.W., Khayal I.S., McGue C., Saraswathy S., Pirzkall A., Cha S., Lamborn K.R., Chang S.M., Berger M.S., Nelson S.J. Relationship of pre-surgery metabolic and physiological MR imaging parameters to survival for patients with untreated GBM. J. Neurooncol 2009, 91:337-351.
21. Faria J., Romao L., Martins S., Alves T., Mendes F.A., de Faria G.P., Hollanda R., Takiya C., Chimelli L., Morandi V., de Souza J.M., Abreu J.G., Moura Neto V. Interactive properties of human glioblastoma cells with brain neurons in culture and neuronal modulation of glial laminin organization. Differentiation 2006, 74:562-572.
22. Kanu O.O., Mehta A., Di C., Lin N., Bortoff K., Bigner D.D., Yan H., Adamson D.C. Glioblastoma multiforme: a review of therapeutic targets. Expert Opin. Ther. Targets 2009, 13:701-718.
23. Hydbring P., Larsson L.G. Tipping the balance: Cdk2 enables Myc to suppress senescence. Cancer Res. 2010, 70:6687-6691.
24. Maher E.A., Furnari F.B., Bachoo R.M., Rowitch D.H., Louis D.N., Cavenee W.K., DePinho R.A. Malignant glioma: genetics and biology of a grave matter. Genes Dev. 2001, 15:1311-1333.
25. Golestaneh N., Mishra B. TGF-beta, neuronal stem cells and glioblastoma. Oncogene 2005, 24:5722-5730.
26. Hilton D.A., Penney M., Pobereskin L., Sanders H., Love S. Histological indicators of prognosis in glioblastomas: retinoblastoma protein expression and oligodendroglial differentiation indicate improved survival. Histopathology 2004, 44:555-560.
27. Verhaak R.G., Hoadley K.A., Purdom E., Wang V., Qi Y., Wilkerson M.D., Miller C.R., Ding L., Golub T., Mesirov J.P., Alexe G., Lawrence M., O'Kelly M., Tamayo P., Weir B.A., Gabriel S., Winckler W., Gupta S., Jakkula L., Feiler H.S., Hodgson J.G., James C.D., Sarkaria J.N., Brennan C., Kahn A., Spellman P.T., Wilson R.K., Speed T.P., Gray J.W., Meyerson M., Getz G., Perou C.M., Hayes D.N. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010, 17:98-110.
28. de Faria G.P., de Oliveira J.A., de Oliveira J.G.P., Romano S.D., Neto V.M., Maia R.C. Differences in the expression pattern of P-glycoprotein and MRP1 in low-grade and high-grade gliomas. Cancer Investig. 2008, 26:883-889.
29. Chaudhary P.M., Roninson I.B. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 1991, 66:85-94.
30. Patru C., Romao L., Varlet P., Coulombel L., Raponi E., Cadusseau J., Renault-Mihara F., Thirant C., Leonard N., Berhneim A., Mihalescu-Maingot M., Haiech J., Bieche I., Moura-Neto V., Daumas-Duport C., Junier M.P., Chneiweiss H. CD133, CD15/SSEA-1, CD34 or side populations do not resume tumor-initiating properties of long-term cultured cancer stem cells from human malignant glio-neuronal tumors. BMC Cancer 2010, 10:66.
31. Liu G., Akasaki Y., Khong H.T., Wheeler C.J., Das A., Black K.L., Yu J.S. Cytotoxic T cell targeting of TRP-2 sensitizes human malignant glioma to chemotherapy. Oncogene 2005, 24:5226-5234.
32. Lee J., Kotliarova S., Kotliarov Y., Li A., Su Q., Donin N.M., Pastorino S., Purow B.W., Christopher N., Zhang W., Park J.K., Fine H.A. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 2006, 9:391-403.
33. Soeda A., Inagaki A., Oka N., Ikegame Y., Aoki H., Yoshimura S., Nakashima S., Kunisada T., Iwama T. Epidermal growth factor plays a crucial role in mitogenic regulation of human brain tumor stem cells. J. Biol. Chem. 2008, 283:10958-10966.
34. Prados M.D., Lamborn K.R., Chang S., Burton E., Butowski N., Malec M., Kapadia A., Rabbitt J., Page M.S., Fedoroff A., Xie D., Kelley S.K. Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. Neuro Oncol. 2006, 8:67-78.
35. Prados M.D., Chang S.M., Butowski N., DeBoer R., Parvataneni R., Carliner H., Kabuubi P., Ayers-Ringler J., Rabbitt J., Page M., Fedoroff A., Sneed P.K., Berger M.S., McDermott M.W., Parsa A.T., Vandenberg S., James C.D., Lamborn K.R., Stokoe D., Haas-Kogan D.A. Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J. Clin. Oncol. 2009, 27:579-584.
36. Rich J.N., Reardon D.A., Peery T., Dowell J.M., Quinn J.A., Penne K.L., Wikstrand C.J., Van Duyn L.B., Dancey J.E., McLendon R.E., Kao J.C., Stenzel T.T., Ahmed Rasheed B.K., Tourt-Uhlig S.E., Herndon J.E., Vredenburgh J.J., Sampson J.H., Friedman A.H., Bigner D.D., Friedman H.S. Phase II trial of gefitinib in recurrent glioblastoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2004, 22:133-142.
37. Yuan T.L., Cantley L.C. PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008, 27:5497-5510.
38. Groszer M., Erickson R., Scripture-Adams D.D., Lesche R., Trumpp A., Zack J.A., Kornblum H.I., Liu X., Wu H. Negative regulation of neural stem/progenitor cell proliferation by the Pten tumor suppressor gene in vivo. Science 2001, 294:2186-2189.
39. Chang S.M., Wen P., Cloughesy T., Greenberg H., Schiff D., Conrad C., Fink K., Robins H.I., De Angelis L., Raizer J., Hess K., Aldape K., Lamborn K.R., Kuhn J., Dancey J., Prados M.D. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest. New Drugs 2005, 23:357-361.
40. Cloughesy T.F., Yoshimoto K., Nghiemphu P., Brown K., Dang J., Zhu S., Hsueh T., Chen Y., Wang W., Youngkin D., Liau L., Martin N., Becker D., Bergsneider M., Lai A., Green R., Oglesby T., Koleto M., Trent J., Horvath S., Mischel P.S., Mellinghoff I.K., Sawyers C.L. Antitumor activity of rapamycin in a phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med. 2008, 5:e8.
41. Doherty L., Gigas D.C., Kesari S., Drappatz J., Kim R., Zimmerman J., Ostrowsky L., Wen P.Y. Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas. Neurology 2006, 67:156-158.
42. Reardon D.A., Desjardins A., Vredenburgh J.J., Gururangan S., Friedman A.H., Herndon J.E., Marcello J., Norfleet J.A., McLendon R.E., Sampson J.H., Friedman H.S. Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. J. Neurooncol 2010, 96:219-230.
43. Berk A.J. Adenoviridae: The Viruses and Their Replication 2007, Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia, Pennsylvania, USA. 5th ed.
44. Jiang H., Gomez-Manzano C., Aoki H., Alonso M.M., Kondo S., McCormick F., Xu J., Kondo Y., Bekele B.N., Colman H., Lang F.F., Fueyo J. Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death. J. Natl. Cancer Inst. 2007, 99:1410-1414.
45. Vredenburgh J.J., Desjardins A., Herndon J.E., Marcello J., Reardon D.A., Quinn J.A., Rich J.N., Sathornsumetee S., Gururangan S., Sampson J., Wagner M., Bailey L., Bigner D.D., Friedman A.H., Friedman H.S. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J. Clin. Oncol. 2007, 25:4722-4729.
46. Vredenburgh J.J., Desjardins A., Herndon J.E., Dowell J.M., Reardon D.A., Quinn J.A., Rich J.N., Sathornsumetee S., Gururangan S., Wagner M., Bigner D.D., Friedman A.H., Friedman H.S. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2007, 13:1253-1259.
47. Batchelor T.T., Sorensen A.G., di Tomaso E., Zhang W.T., Duda D.G., Cohen K.S., Kozak K.R., Cahill D.P., Chen P.J., Zhu M., Ancukiewicz M., Mrugala M.M., Plotkin S., Drappatz J., Louis D.N., Ivy P., Scadden D.T., Benner T., Loeffler J.S., Wen P.Y., Jain R.K. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007, 11:83-95.
48. Calabrese C., Poppleton H., Kocak M., Hogg T.L., Fuller C., Hamner B., Oh E.Y., Gaber M.W., Finklestein D., Allen M., Frank A., Bayazitov I.T., Zakharenko S.S., Gajjar A., Davidoff A., Gilbertson R.J. A perivascular niche for brain tumor stem cells. Cancer Cell 2007, 11:69-82.
49. Palma V., Lim D.A., Dahmane N., Sanchez P., Brionne T.C., Herzberg C.D., Gitton Y., Carleton A., Alvarez-Buylla A., Ruiz i Altaba A. Sonic hedgehog controls stem cell behavior in the postnatal and adult brain. Development 2005, 132:335-344.
50. Cui D., Xu Q., Wang K., Che X. Gli1 is a potential target for alleviating multidrug resistance of gliomas. J. Neurol. Sci. 2010, 288:156-166.
51. Takezaki T., Hide T., Takanaga H., Nakamura H., Kuratsu J., Kondo T. Essential role of the hedgehog signaling pathway in human glioma-initiating cells. Cancer Sci. 2011, 102:1306-1312.
52. Clement V., Sanchez P., de Tribolet N., Radovanovic I., Ruiz i Altaba A. HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. Curr. Biol. 2007, 17:165-172.
53. Zbinden M., Duquet A., Lorente-Trigos A., Ngwabyt S.N., Borges I., Ruiz i Altaba A. NANOG regulates glioma stem cells and is essential in vivo acting in a cross-functional network with GLI1 and p53. EMBO J. 2010, 29:2659-2674.
54. Becher O.J., Hambardzumyan D., Fomehenko E.I., Momota H., Mainwaring L., Bleau A.M., Katz A.M., Edgar M., Kenney A.M., Cordon-Cardo C., Blasberg R.G., Holland E.C. Gli activity correlates with tumor grade in platelet-derived growth factor-induced gliomas. Cancer Res. 2008, 68:2241-2249.
55. Bar E.E., Chaudhry A., Lin A., Fan X., Schreck K., Matsui W., Piccirillo S., Vescovi A.L., DiMeco F., Olivi A., Eberharta C.G. Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. Stem Cells 2007, 25:2524-2533.
56. Feldmann G., Fendrich V., McGovern K., Bedja D., Bisht S., Alvarez H., Koorstra J.B., Habbe N., Karikari C., Mullendore M., Gabrielson K.L., Sharma R., Matsui W., Maitra A. An orally bioavailable small-molecule inhibitor of hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer. Mol. Cancer Ther. 2008, 7:2725-2735.
57. Ulasov I.V., Nandi S., Dey M., Sonabend A.M., Lesniak M.S. Inhibition of sonic hedgehog and Notch pathways enhances sensitivity of CD133(+) glioma stem cells to temozolomide therapy. Mol. Med. 2011, 17:103-112.
58. Mintz B., Illmensee K. Normal genetically mosaic mice produced from malignant teratocarcinoma cells. Proc. Natl. Acad. Sci. U. S. A. 1975, 72:3585-3589.
59. Kulesa P.M., Kasemeier-Kulesa J.C., Teddy J.M., Margaryan N.V., Seftor E.A., Seftor R.E., Hendrix M.J. Reprogramming metastatic melanoma cells to assume a neural crest cell-like phenotype in an embryonic microenvironment. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:3752-3757.
60. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 1971, 285:1182-1186.
61. Ahluwalia M.S., Gladson C.L. Progress on antiangiogenic therapy for patients with malignant glioma. J. Oncol. 2010, 2010:689018.
62. Rahman R., Smith S., Rahman C., Grundy R. Antiangiogenic therapy and mechanisms of tumor resistance in malignant glioma. J. Oncol. 2010, 2010:251231.
63. Sullivan L.A., Brekken R.A. The VEGF family in cancer and antibody-based strategies for their inhibition. MAbs 2010, 2:165-175.
64. Huang H., Held-Feindt J., Buhl R., Mehdorn H.M., Mentlein R. Expression of VEGF and its receptors in different brain tumors. Neurol. Res. 2005, 27:371-377.
65. Miyagami M., Katayama Y. Angiogenesis of glioma: evaluation of ultrastructural characteristics of microvessels and tubular bodies (Weibel-Palade) in endothelial cells and immunohistochemical findings with VEGF and p53 protein. Med. Mol. Morphol. 2005, 38:36-42.
66. Esser S., Lampugnani M.G., Corada M., Dejana E., Risau W. Vascular endothelial growth factor induces VE-cadherin tyrosine phosphorylation in endothelial cells. J. Cell Sci. 1998, 111(Pt 13):1853-1865.
67. Shibuya M. Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J. Biochem. Mol. Biol. 2006, 39:469-478.
68. Bergers G., Benjamin L.E. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 2003, 3:401-410.
69. Carneiro-Lobo T.C., Konig S., Machado D.E., Nasciutti L.E., Forni M.F., Francischetti I.M., Sogayar M.C., Monteiro R.Q. Ixolaris, a tissue factor inhibitor, blocks primary tumor growth and angiogenesis in a glioblastoma model. J. Thromb. Haemost. 2009, 7:1855-1864.
70. de Bouard S., Guillamo J.S. Angiogenesis and anti-angiogenic strategies for glioblastoma. Bull. Cancer 2005, 92:360-372.
71. Desjardins A., Reardon D.A., Herndon J.E., Marcello J., Quinn J.A., Rich J.N., Sathornsumetee S., Gururangan S., Sampson J., Bailey L., Bigner D.D., Friedman A.H., Friedman H.S., Vredenburgh J.J. Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clin. Cancer Res. 2008, 14:7068-7073.
72. Riina H.A., Knopman J., Greenfield J.P., Fralin S., Gobin Y.P., Tsiouris A.J., Souweidane M.M., Boockvar J.A. Balloon-assisted superselective intra-arterial cerebral infusion of bevacizumab for malignant brainstem glioma. A technical note. Interv. Neuroradiol. 2010, 16:71-76.
73. Dietrich J., Wang D., Batchelor T.T. Cediranib: profile of a novel anti-angiogenic agent in patients with glioblastoma. Expert Opin. Investig. Drugs 2009, 18:1549-1557.
74. Batchelor T.T., Duda D.G., di Tomaso E., Ancukiewicz M., Plotkin S.R., Gerstner E., Eichler A.F., Drappatz J., Hochberg F.H., Benner T., Louis D.N., Cohen K.S., Chea H., Exarhopoulos A., Loeffler J.S., Moses M.A., Ivy P., Sorensen A.G., Wen P.Y., Jain R.K. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J. Clin. Oncol. 2010, 28:2817-2823.
75. Nilsson I., Bahram F., Li X., Gualandi L., Koch S., Jarvius M., Soderberg O., Anisimov A., Kholova I., Pytowski B., Baldwin M., Yla-Herttuala S., Alitalo K., Kreuger J., Claesson-Welsh L. VEGF receptor 2/-3 heterodimers detected in situ by proximity ligation on angiogenic sprouts. EMBO J. 2010, 29:1377-1388.
76. Tammela T., Zarkada G., Wallgard E., Murtomaki A., Suchting S., Wirzenius M., Waltari M., Hellstrom M., Schomber T., Peltonen R., Freitas C., Duarte A., Isoniemi H., Laakkonen P., Christofori G., Yla-Herttuala S., Shibuya M., Pytowski B., Eichmann A., Betsholtz C., Alitalo K. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature 2008, 454:656-660.
77. Iwamoto F.M., Fine H.A. Bevacizumab for malignant gliomas. Arch. Neurol. 2010, 67:285-288.
78. Scott B.J., Quant E.C., McNamara M.B., Ryg P.A., Batchelor T.T., Wen P.Y. Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors. Neuro Oncol. 2010, 12:603-607.
79. Paez-Ribes M., Allen E., Hudock J., Takeda T., Okuyama H., Vinals F., Inoue M., Bergers G., Hanahan D., Casanovas O. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009, 15:220-231.
80. Zagzag D., Amirnovin R., Greco M.A., Yee H., Holash J., Wiegand S.J., Zabski S., Yancopoulos G.D., Grumet M. Vascular apoptosis and involution in gliomas precede neovascularization: a novel concept for glioma growth and angiogenesis. Lab. Invest. 2000, 80:837-849.
81. Lucio-Eterovic A.K., Piao Y., de Groot J.F. Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy. Clin. Cancer Res. 2009, 15:4589-4599.
82. di Tomaso E., Snuderl M., Kamoun W.S., Duda D.G., Auluck P.K., Fazlollahi L., Andronesi O.C., Frosch M.P., Wen P.Y., Plotkin S.R., Hedley-Whyte E.T., Sorensen A.G., Batchelor T.T., Jain R.K. Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape. Cancer Res. 2011, 71:19-28.
83. Miletic H., Niclou S.P., Johansson M., Bjerkvig R. Anti-VEGF therapies for malignant glioma: treatment effects and escape mechanisms. Expert Opin. Ther. Targets 2009, 13:455-468.
84. Kioi M., Vogel H., Schultz G., Hoffman R.M., Harsh G.R., Brown J.M. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J. Clin. Invest. 2010, 120:694-705.
85. Ceradini D.J., Kulkarni A.R., Callaghan M.J., Tepper O.M., Bastidas N., Kleinman M.E., Capla J.M., Galiano R.D., Levine J.P., Gurtner G.C. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat. Med. 2004, 10:858-864.
86. Jin D.K., Shido K., Kopp H.G., Petit I., Shmelkov S.V., Young L.M., Hooper A.T., Amano H., Avecilla S.T., Heissig B., Hattori K., Zhang F., Hicklin D.J., Wu Y., Zhu Z., Dunn A., Salari H., Werb Z., Hackett N.R., Crystal R.G., Lyden D., Rafii S. Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes. Nat. Med. 2006, 12:557-567.
87. Kenig S., Alonso M.B., Mueller M.M., Lah T.T. Glioblastoma and endothelial cells cross-talk, mediated by SDF-1, enhances tumour invasion and endothelial proliferation by increasing expression of cathepsins B, S, and MMP-9. Cancer Lett. 2010, 289:53-61.
88. Charles N.A., Holland E.C., Gilbertson R., Glass R., Kettenmann H. The brain tumor microenvironment. Glia 2011, 59:1169-1180.
89. Daginakatte G.C., Gianino S.M., Zhao N.W., Parsadanian A.S., Gutmann D.H. Increased c-Jun-NH2-kinase signaling in neurofibromatosis-1 heterozygous microglia drives microglia activation and promotes optic glioma proliferation. Cancer Res. 2008, 68:10358-10366.
90. Platten M., Kretz A., Naumann U., Aulwurm S., Egashira K., Isenmann S., Weller M. Monocyte chemoattractant protein-1 increases microglial infiltration and aggressiveness of gliomas. Ann. Neurol. 2003, 54:388-392.
91. Fonseca A.C., Romao L., Amaral R.F., Assad Kahn S., Lobo D., Martins S., Marcondes de Souza J., Moura-Neto V., Lima F.R. Microglial stress inducible protein 1 promotes proliferation and migration in human glioblastoma cells. Neuroscience 2012, 200:130-141.
92. Markovic D.S., Glass R., Synowitz M., Rooijen N., Kettenmann H. Microglia stimulate the invasiveness of glioma cells by increasing the activity of metalloprotease-2. J. Neuropathol. Exp. Neurol. 2005, 64:754-762.
93. Alves T.R., Lima F.R., Kahn S.A., Lobo D., Dubois L.G., Soletti R., Borges H., Neto V.M. Glioblastoma cells: a heterogeneous and fatal tumor interacting with the parenchyma. Life Sci. 2011, 89:532-539.
94. Rao J.S. Molecular mechanisms of glioma invasiveness: the role of proteases. Nat. Rev. Cancer 2003, 3:489-501.
95. Erlich R.B., Kahn S.A., Lima F.R., Muras A.G., Martins R.A., Linden R., Chiarini L.B., Martins V.R., Moura Neto V. STI1 promotes glioma proliferation through MAPK and PI3K pathways. Glia 2007, 55:1690-1698.
96. Sawada M., Imai F., Suzuki H., Hayakawa M., Kanno T., Nagatsu T. Brain-specific gene expression by immortalized microglial cell-mediated gene transfer in the mammalian brain. FEBS Lett. 1998, 433:37-40.
97. Ribot E., Bouzier-Sore A.K., Bouchaud V., Miraux S., Delville M.H., Franconi J.M., Voisin P. Microglia used as vehicles for both inducible thymidine kinase gene therapy and MRI contrast agents for glioma therapy. Cancer Gene Ther. 2007, 14:724-737.
98. Bhat N.R., Fan F. Adenovirus infection induces microglial activation: involvement of mitogen-activated protein kinase pathways. Brain Res. 2002, 948:93-101.
99. Balcaitis S., Weinstein J.R., Li S., Chamberlain J.S., Moller T. Lentiviral transduction of microglial cells. Glia 2005, 50:48-55.
100. Lun X., Alain T., Zemp F.J., Zhou H., Rahman M.M., Hamilton M.G., McFadden G., Bell J., Senger D.L., Forsyth P.A. Myxoma virus virotherapy for glioma in immunocompetent animal models: optimizing administration routes and synergy with rapamycin. Cancer Res. 2010, 70:598-608.
101. Kateb B., Van Handel M., Zhang L., Bronikowski M.J., Manohara H., Badie B. Internalization of MWCNTs by microglia: possible application in immunotherapy of brain tumors. Neuroimage 2007, 37(Suppl. 1):S9-S17.
102. Zhao D., Alizadeh D., Zhang L., Liu W., Farrukh O., Manuel E., Diamond D.J., Badie B. Carbon nanotubes enhance CpG uptake and potentiate antiglioma immunity. Clin. Cancer Res. 2011, 17:771-782.
103. Yu H., Kortylewski M., Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat. Rev. Immunol. 2007, 7:41-51.
104. O'Farrell A.M., Liu Y., Moore K.W., Mui A.L. IL-10 inhibits macrophage activation and proliferation by distinct signaling mechanisms: evidence for Stat3-dependent and -independent pathways. EMBO J. 1998, 17:1006-1018.
105. Hussain S.F., Kong L.Y., Jordan J., Conrad C., Madden T., Fokt I., Priebe W., Heimberger A.B. A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients. Cancer Res. 2007, 67:9630-9636.
106. Buonerba C., Di Lorenzo G., Marinelli A., Federico P., Palmieri G., Imbimbo M., Conti P., Peluso G., De Placido S., Sampson J.H. A comprehensive outlook on intracerebral therapy of malignant gliomas. Crit. Rev. Oncol. Hematol. 2011, 80:54-68.
107. Reiter Y. Recombinant immunotoxins in targeted cancer cell therapy. Adv. Cancer Res. 2001, 81:93-124.
108. Weaver M., Laske D.W. Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. J. Neurooncol 2003, 65:3-13.
109. Libermann T.A., Nusbaum H.R., Razon N., Kris R., Lax I., Soreq H., Whittle N., Waterfield M.D., Ullrich A., Schlessinger J. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature 1985, 313:144-147.
110. Puri R.K., Hoon D.S., Leland P., Snoy P., Rand R.W., Pastan I., Kreitman R.J. Preclinical development of a recombinant toxin containing circularly permuted interleukin 4 and truncated Pseudomonas exotoxin for therapy of malignant astrocytoma. Cancer Res. 1996, 56:5631-5637.
111. Kawakami K., Kawakami M., Puri R.K. Overexpressed cell surface interleukin-4 receptor molecules can be successfully targeted for antitumor cytotoxin therapy. Crit. Rev. Immunol. 2001, 21:299-310.
112. Rand R.W., Kreitman R.J., Patronas N., Varricchio F., Pastan I., Puri R.K. Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma. Clin. Cancer Res. 2000, 6:2157-2165.
113. Rainov N.G., Heidecke V. Long term survival in a patient with recurrent malignant glioma treated with intratumoral infusion of an IL4-targeted toxin (NBI-3001). J. Neurooncol 2004, 66:197-201.
114. Kunwar S., Prados M.D., Chang S.M., Berger M.S., Lang F.F., Piepmeier J.M., Sampson J.H., Ram Z., Gutin P.H., Gibbons R.D., Aldape K.D., Croteau D.J., Sherman J.W., Puri R.K. Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J. Clin. Oncol. 2007, 25:837-844.
115. Kunwar S., Chang S., Westphal M., Vogelbaum M., Sampson J., Barnett G., Shaffrey M., Ram Z., Piepmeier J., Prados M., Croteau D., Pedain C., Leland P., Husain S.R., Joshi B.H., Puri R.K. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma. Neuro Oncol. 2010, 12:871-881.
116. Sampson J.H., Akabani G., Archer G.E., Bigner D.D., Berger M.S., Friedman A.H., Friedman H.S., Herndon J.E., Kunwar S., Marcus S., McLendon R.E., Paolino A., Penne K., Provenzale J., Quinn J., Reardon D.A., Rich J., Stenzel T., Tourt-Uhlig S., Wikstrand C., Wong T., Williams R., Yuan F., Zalutsky M.R., Pastan I. Progress report of a phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J. Neurooncol 2003, 65:27-35.
117. Soletti R.C., de Faria G.P., Vernal J., Terenzi H., Anderluh G., Borges H.L., Moura-Neto V., Gabilan N.H. Potentiation of anticancer-drug cytotoxicity by sea anemone pore-forming proteins in human glioblastoma cells. Anticancer Drugs 2008, 19:517-525.
118. Soletti R.C., Alves T., Vernal J., Terenzi H., Anderluh G., Borges H.L., Gabilan N.H., Moura-Neto V. Inhibition of MAPK/ERK, PKC and CaMKII signaling blocks cytolysin-induced human glioma cell death. Anticancer Res. 2010, 30:1209-1215.
119. Lavie Y., Liscovitch M. Changes in lipid and protein constituents of rafts and caveolae in multidrug resistant cancer cells and their functional consequences. Glycoconj. J. 2000, 17:253-259.
120. Bakrac B., Anderluh G. Molecular mechanism of sphingomyelin-specific membrane binding and pore formation by actinoporins. Adv. Exp. Med. Biol. 2010, 677:106-115.
121. Roger M., Clavreul A., Venier-Julienne M.C., Passirani C., Montero-Menei C., Menei P. The potential of combinations of drug-loaded nanoparticle systems and adult stem cells for glioma therapy. Biomaterials 2011, 32:2106-2116.
122. Kuroda J., Kuratsu J., Yasunaga M., Koga Y., Kenmotsu H., Sugino T., Matsumura Y. Antitumor effect of NK012, a 7-ethyl-10-hydroxycamptothecin-incorporating polymeric micelle, on U87MG orthotopic glioblastoma in mice compared with irinotecan hydrochloride in combination with bevacizumab. Clin. Cancer Res. 2010, 16:521-529.
123. Lamprecht A., Benoit J.P. Etoposide nanocarriers suppress glioma cell growth by intracellular drug delivery and simultaneous P-glycoprotein inhibition. J. Control. Release 2006, 112:208-213.
124. Mesiwala A.H., Farrell L., Wenzel H.J., Silbergeld D.L., Crum L.A., Winn H.R., Mourad P.D. High-intensity focused ultrasound selectively disrupts the blood-brain barrier in vivo. Ultrasound Med. Biol. 2002, 28:389-400.
125. Chen S.Y., Hayashida Y., Chen M.Y., Xie H.T., Tseng S.C. A new isolation method of human limbal progenitor cells by maintaining close association with their niche cells. Tissue Eng. Part C Methods 2010, 17:537-548.
126. Kato T., Natsume A., Toda H., Iwamizu H., Sugita T., Hachisu R., Watanabe R., Yuki K., Motomura K., Bankiewicz K., Wakabayashi T. Efficient delivery of liposome-mediated MGMT-siRNA reinforces the cytotoxity of temozolomide in GBM-initiating cells. Gene Ther. 2010, 17:1363-1371.
127. Bass B.L. Double-stranded RNA as a template for gene silencing. Cell 2000, 101:235-238.
128. de Fougerolles A., Vornlocher H.P., Maraganore J., Lieberman J. Interfering with disease: a progress report on siRNA-based therapeutics, nature reviews. Drug Discov. 2007, 6:443-453.
129. Seltzer M.J., Bennett B.D., Joshi A.D., Gao P., Thomas A.G., Ferraris D.V., Tsukamoto T., Rojas C.J., Slusher B.S., Rabinowitz J.D., Dang C.V., Riggins G.J. Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res. 2010, 70:8981-8987.
130. Xu Y., Stamenkovic I., Yu Q. CD44 attenuates activation of the hippo signaling pathway and is a prime therapeutic target for glioblastoma. Cancer Res. 2010, 70:2455-2464.
131. Rolle K., Nowak S., Wyszko E., Nowak M., Zukiel R., Piestrzeniewicz R., Gawronska I., Barciszewska M.Z., Barciszewski J. Promising human brain tumors therapy with interference RNA intervention (iRNAi). Cancer Biol. Ther. 2010, 9:396-406.
132. Alves T.R., da Fonseca A.C., Nunes S.S., da Silva A.O., Dubois L.G., Faria J., Kahn S.A., Viana N.B., Marcondes J., Legrand C., Moura-Neto V., Morandi V. Tenascin-C in the extracellular matrix promotes the selection of highly proliferative and tubulogenesis-defective endothelial cells. Exp. Cell Res. 2011, 317:2073-2085.
133. [Accessed 02.13.12] University of Texas MD Anderson Cancer Center, 2008. Phase I Trial of Conditionally Replication-Competent Adenovirus (Delta-24-RGD) for Recurrent Malignant Gliomas. http://utm-ext01a.mdacc.tmc.edu/dept/prot/clinicaltrialswp.nsf/Index/ID01-310.
134. [Acessed 02.13.12] National Health Institute Clinical Trials. Found 114 studies with search of: anti angiogenic therapy and glioblastoma. http://www.clinicaltrials.gov/ct2/results?term=anti+angiogenic+therapy+and+glioblastoma.
135. [Accessed 02.13.12] National Health Institute Clinical Trials. Found 81 studies with search of: bevacizumab and glioblastoma. http://www.clinicaltrials.gov/ct2/results?term=bevacizumab+and+glioblastoma.
136. [Accessed 02.13.12] National Health Institute Clinical Trials, 2011. Bevacizumab and AZD2171 in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma. http://www.clinicaltrials.gov/ct2/show/NCT00458731?term=bevacizumab+and+cediranib+and+glioblastoma&rank=1.
137. [Accessed 02.13.12]. National Health Institute Clinical Trials, 2009. Study of therapy with TransMID™ compared to best standard of care in patients with glioblastoma multiforme. http://clinicaltrials.gov/ct2/show/NCT00083447.